Century Therapeutics, Inc. (IPSC) - Q1 2026 Filing Summary
Business Context and Reporting Period
This summary covers the Quarterly Report on Form 10-Q for Century Therapeutics, Inc. for the period ended March 31, 2026. Century is a biotechnology company developing allogeneic cell therapies for autoimmune diseases (including Type 1 diabetes) and cancer using induced pluripotent stem cells (iPSCs). The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Collaboration Revenue | $0 | $109.2 million |
| Total Operating Expenses | $23.7 million | $35.0 million |
| Net Loss | $(21.6) million | $76.6 million (Income) |
| Cash, Cash Equivalents, and Investments | $217.0 million | $113.3 million |
| Net Cash Used in Operating Activities | $(25.3) million | $(34.6) million |
| Accumulated Deficit | $(813.6) million | $(705.8) million |
Material Changes vs. Prior Period
- Revenue Collapse: Collaboration revenue dropped to zero in Q1 2026 compared to $109.2 million in Q1 2025. This is due to the termination of the Bristol-Myers Squibb collaboration agreement effective March 12, 2025, which resulted in the recognition of the remaining transaction price in the prior year.
- Expense Reduction: Total operating expenses decreased by $11.3 million year-over-year. Research and Development (R&D) expenses fell by $9.5 million, and General and Administrative (G&A) expenses fell by $1.8 million. These reductions were driven by a reduction in R&D staff and portfolio prioritization decisions made in late 2025.
- Capital Raise: In January 2026, the company completed a private placement raising approximately $126.4 million in net proceeds. This significantly increased total assets and liquidity compared to the prior year.
- Investment Activity: The company shifted from a net provider of cash in investing activities in Q1 2025 to a net user of $112.6 million in Q1 2026, primarily due to the acquisition of $140.7 million in fixed maturity securities.
Outlook, Risks, and Management Commentary
- Liquidity Runway: Management believes current cash, cash equivalents, and investments of $217.0 million are sufficient to fund operations and capital expenditures into the first quarter of 2029.
- Strategic Priorities: The company is prioritizing the development of CNTY-813 (iPSC-derived islet program for Type 1 diabetes) and CNTY-308 (CAR-iT cell therapy). An IND for CNTY-813 is expected in Q4 2026. Clinical activities for CNTY-101 have been redirected to an investigator-sponsored trial (CARAMEL).
- Risks: Key risks include the need for additional financing to fund future operations, the uncertainty of clinical trial outcomes, regulatory approval timelines, and the novelty of the iPSC technology platform. The company has a full valuation allowance against its deferred tax assets due to a history of losses.
- Unusual Items: The Q1 2025 results were heavily skewed by the one-time revenue recognition from the BMS termination. Q1 2026 reflects a return to a pre-revenue, development-stage financial profile.
Investor Verification Checklist
- Verify the specific timeline and milestones for the CNTY-813 IND submission expected in Q4 2026.
- Confirm the details of the January 2026 private placement, including the exercise price of warrants ($2.60) and expiration terms.
- Review the impact of the Bristol-Myers Squibb termination on future royalty or milestone potential (none expected).
- Monitor the burn rate relative to the stated runway into Q1 2029, given the cessation of collaboration revenue.
- Assess the progress of the CARAMEL investigator-sponsored trial for CNTY-101 as a proxy for clinical data generation.